If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Five year distribution agreement

4 Jan 2010 07:00

RNS Number : 9261E
Immunodiagnostic Systems Hldgs PLC
04 January 2010
 



Immunodiagnostic Systems Holdings plc

Five year distribution agreement

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that Technogenetics s.r.l. ("Technogenetics") of Milan, Italy has signed a five year distribution agreement with A. Menarini Diagnostics ("Menarini") covering Europe for an automated test system, the Zenit RA, together with a panel of 21 tests for the diagnosis of autoimmune diseases. The Zenit RA is an OEM version of the IDS-iSYS system.

On 5 October 2009 IDS announced that it had signed an OEM manufacturing and supply agreement with Technogenetics, a subsidiary of Bouty S.p.A, the clinical diagnostics company (see RNS Reach number 1950A). As part of this agreement IDS will supply IDS-iSYS systems and consumables to Technogenetics on an OEM basis. These systems, branded as the Zenit RA, and consumables will be sold by Menarini as 'closed system' instruments throughout the whole of Europe and countries of the former Soviet Union such as Russia and Ukraine. Menarini is a leading company in the diagnostic field, with 14 direct subsidiaries, 1,000 employees and a consolidated turnover of 320 million Euros.

Commenting on the distribution agreement, Lorenzo Castellini, President of the Bouty Group, said: "We expect that over the five years the distribution agreement with A. Menarini Diagnostics will generate approximately €12 million in revenues from sales of diagnostic kits manufactured by Technogenetics with additional income from sales of instruments and ancillary reagents supplied by IDS."

Roger Duggan, CEO of IDS, said: "We're very pleased to see that our collaboration with Technogenetics is about to bear fruit and the deal signed between Technogenetics and Menarini significantly expands the route to market for Technogenetics’ autoimmune products. This can only enhance future sales of IDS-manufactured instruments and ancillary reagents across Europe, a great ‘upside’ to our agreement with Technogenetics.”

 

Enquiries:

 

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

David Evans, Chairman

 

Roger Duggan, CEO

 

 

 

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

 

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKKNDQBBKDODK
Date   Source Headline
1st Jun 20117:00 amRNSAppointment of Non-Executive Director
9th May 20117:00 amRNSChange of contract terms
28th Apr 20117:00 amRNSTotal Voting Rights
12th Apr 20118:34 amRNSExercise of Share Options and Total Voting Rights
6th Apr 20117:00 amRNSTrading update
28th Mar 20117:35 amRNSExclusive Licence Agreement
1st Mar 20117:00 amRNSDirector/PDMR Shareholding
3rd Feb 201110:34 amRNSDirector/PDMR Shareholding
11th Jan 20113:40 pmRNSDirector/PDMR Shareholding
30th Nov 20107:00 amRNSHalf Yearly Report
12th Nov 20104:41 pmRNSSecond Price Monitoring Extn
12th Nov 20104:35 pmRNSPrice Monitoring Extension
1st Nov 201011:22 amRNSHolding(s) in Company
5th Oct 20108:56 amRNSPosting of Report and Accounts and Notice of AGM
5th Oct 20107:00 amRNSTrading Update
27th Sep 20107:00 amRNSIssue of Equity
21st Sep 20104:35 pmRNSPrice Monitoring Extension
20th Sep 201010:33 amRNSHolding(s) in Company
13th Sep 20107:00 amRNSAcquisition & Research Agreement
25th Aug 20104:06 pmRNSResult of AGM
25th Aug 20107:00 amRNSAGM Statement
26th Jul 20101:00 pmRNSExercise of Share Options and Total Voting Rights
26th Jul 20107:00 amRNSNew specialist assay launched for IDS-iSYS
20th Jul 20107:00 amRNSDirector/PDMR Shareholding
12th Jul 20107:00 amRNSDirectorate Change
12th Jul 20107:00 amRNSFinal Results
29th Jun 20107:00 amRNSReceipt of FDA 510(k) clearances
16th Jun 20104:40 pmRNSSecond Price Monitoring Extn
16th Jun 20104:35 pmRNSPrice Monitoring Extension
14th Jun 20104:35 pmRNSPrice Monitoring Extension
11th Jun 20104:35 pmRNSPrice Monitoring Extension
10th Jun 20104:35 pmRNSPrice Monitoring Extension
26th May 20104:40 pmRNSSecond Price Monitoring Extn
26th May 20104:35 pmRNSPrice Monitoring Extension
10th May 20107:00 amRNSExercise of Share Options
12th Apr 20107:00 amRNSTrading Statement
31st Mar 201012:24 pmRNSTotal Voting Rights
31st Mar 20107:00 amRNSNew specialist assays launched for IDS-iSYS
22nd Mar 20107:00 amRNSDirector/PDMR Shareholding
16th Mar 201010:00 amRNSDirector/PDMR Shareholding
23rd Feb 201011:47 amRNSExercise of Share Options
9th Feb 20107:00 amRNSShare options
1st Feb 20109:13 amRNSExercise of Share Options and Total Voting Rights
4th Jan 20107:00 amRNSFive year distribution agreement
21st Dec 20091:15 pmRNSDirector/PDMR Shareholding
18th Dec 20093:18 pmRNSIssue of Equity
11th Dec 20097:00 amRNSDirectorate Change
10th Dec 20097:00 amRNSExercise of Share Options and Directors' Dealings
30th Nov 20097:00 amRNSHalf Yearly Report
18th Nov 200910:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.